Examiner Made Two Legal Errors In Stem Cell Patent Decision Consumer Advocates Say Appeal Brief Asks Wisconsin Alumni Research Foundation s Patent Claims Be Rejected: related news

Examiner Made Two Legal Errors in Stem Cell Patent Decision, Consumer Advocates Say Appeal Brief Asks Wisconsin Alumni Research Foundation's Patent Claims Be Rejected

Examiner Made Two Legal Errors in Stem Cell Patent Decision, Consumer Advocates Say Appeal Brief Asks Wisconsin Alumni Research Foundation's Patent Claims Be Rejected

Examiner Made Two Legal Errors in Stem Cell Patent Decision, Consumer Advocates Say Appeal Brief Asks Wisconsin Alumni Research Foundation's Patent Claims Be Rejected

PRNewswire-USNewswire/ -- Legal papers just filed with the U.S. Patent Office cite two legal errors made by a patent examiner in confirming a patent on human embryonic stem cells and ask its claims be rejected, two consumer groups said today.

Examiner Made Two Legal Errors In Stem Cell Patent Decision, Consumer Advocates Say Appeal Brief Asks Wisconsin Alumni Research Foundation's Patent Claims Be Rejected

SANTA MONICA, CA -- Legal papers just filed with the U.S. Patent Office cite two legal errors made by a patent examiner in confirming a patent on human embryonic stem cells and ask its claims be rejected, two consumer groups said today.

Halliburton Tries To Patent Form Of Patent Trolling

We see all sorts of ridiculous patent applications and patents, but my favorites tend to be the patents that have to do with patents themselves (such as the patent app on a method for filing a patent). However, the folks over at Patently-O have highlighted a fascinating patent application from an attorney at Halliburton, which appears to be an attempt to patent the process of patent trolling. The application covers, quite explicitly, having a company (we'll say Company A) that does not invent something, find a company (Company B) that did invent something, but chose to use trade secret protection, rather than patents. Then, the Company A files a patent covering Company B's technology, and then use the issued patent to get money out of Company B.

Halliburton Applies For Patent-Trolling Patent

An anonymous reader writes "Halliburton, the company many folks know as Dick Cheney's previous employer, has apparently taken an interest in methods of patent trolling. In fact, according to Techdirt, the company has applied for a patent on patent trolling. Specifically, it's applied for a patent on the process of finding a company that protected an invention via trade secret, figuring out what that secret is, patenting it ... and then suing the original company. Hopefully, the patent office rejects this patent, because I somehow doubt that Halliburton is trying to get the patent as a way to block others from patent trolling."

Stem Cell Sciences Reinforces its International Patent Position in Stem Cell Technologies

CAMBRIDGE, England, November 14 /PRNewswire-FirstCall/ -- - European IRES Patent Upheld and UK Patent on Cell Screening Technology Granted - ("Stem Cell Sciences", "SCS", "the Company") IRES Patent Upheld in Appeal Hearing at the EPO Stem Cell Sciences plc

Stem Cell Sciences Reinforces its International Patent Position in Stem Cell Technologies

Stem Cell Sciences plc (AIM:STEM, ASX:STC) announces that European patent no. 0695361 covering its IRES technology was upheld by the European Patent Office in Munich on 12th November 2008. The EPO Technical Board of Appeal dismissed objections against the patent raised by Institut Pasteur on 12th April 2007. SCS' IRES (Internal Ribosome Entry Site) technology enables researchers to monitor the activity of a gene of interest in living cells or tissues without blocking the normal function of the gene. In particular, IRES is important for evaluating the success of gene deletions (knock-outs) or insertions (knock-ins) in stem cells, which is crucial for the successful creation of transgenic mouse and rat disease models.

Stem Cell Sciences Reinforces its International Patent Position in Stem Cell Technologies

Stem Cell Sciences plc (AIM:STEM, ASX:STC) announces that European patent no. 0695361 covering its IRES technology was upheld by the European Patent Office in Munich on 12th November 2008. The EPO Technical Board of Appeal dismissed objections against the patent raised by Institut Pasteur on 12th April 2007. SCS' IRES (Internal Ribosome Entry Site) technology enables researchers to monitor the activity of a gene of interest in living cells or tissues without blocking the normal function of the gene. In particular, IRES is important for evaluating the success of gene deletions (knock-outs) or insertions (knock-ins) in stem cells, which is crucial for the successful creation of transgenic mouse and rat disease models.

Stem Cell Sciences Reinforces its International Patent Position in Stem Cell Technologies

Stem Cell Sciences plc (AIM:STEM, ASX:STC) announces that European patent no. 0695361 covering its IRES technology was upheld by the European Patent Office in Munich on 12th November 2008. The EPO Technical Board of Appeal dismissed objections against the patent raised by Institut Pasteur on 12th April 2007. SCS' IRES (Internal Ribosome Entry Site) technology enables researchers to monitor the activity of a gene of interest in living cells or tissues without blocking the normal function of the gene. In particular, IRES is important for evaluating the success of gene deletions (knock-outs) or insertions (knock-ins) in stem cells, which is crucial for the successful creation of transgenic mouse and rat disease models.

Patent Lawsuit Silly Season: TechCrunch Sued For Patent Infringement After Critical Blog Post

There are different levels of ridiculousness when it comes to patent lawsuits, with the lowest of the low being patent lawsuits based more on spite than on any legitimate claim. For a while, it seemed like Ray Niro's use of the infamous JPG patent, to sue a bunch companies he just didn't like, was perhaps alone in that category. But, it appears that we now have a new entrant. Apparently, some company (who we won't even name, since there's a good chance it's doing this just to get press attention) sued a more well-known competitor for patent infringement, over a location-based services patent. Looking over the patent itself it's difficult to see how it was approved. People were talking about location-based profile matching a decade ago, let alone five years ago when this patent was filed.

Stem Cell Therapeutics Announces Issuance of Australian Patent

Stem Cell Therapeutics Corp. ("SCT") (TSX VENTURE:SSS) has been issued Australian Patent No. 2003250697, entitled "Oligodendrocyte Production from Multipotent Neural Stem Cells". This patent, issued on August 14, 2008, covers methods of producing oligodendrocytes from neural stem cells using granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin 3 (IL-3), or interleukin 5 (IL-5), either in vivo or in cell culture, as well as oligodendrocyte compositions produced by such methods. This is the first patent to issue in this patent family.

Stem Cell Therapeutics Announces Issuance of Australian Patent

Stem Cell Therapeutics Corp. ("SCT") (TSX VENTURE: SSS) has been issued Australian Patent No. 2003250697, entitled "Oligodendrocyte Production from Multipotent Neural Stem Cells". This patent, issued on August 14, 2008, covers methods of producing oligodendrocytes from neural stem cells using granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin 3 (IL-3), or interleukin 5 (IL-5), either in vivo or in cell culture, as well as oligodendrocyte compositions produced by such methods. This is the first patent to issue in this patent family.

Stem Cell Sciences Reinforces its International Patent Position in Stem Cell Technologies

CAMBRIDGE, England, November 14, 2008 /PRNewswire-FirstCall/ --Stem Cell Sciences plc announces that European patent no. 0695361 covering its IRES technology was upheld by the European Patent Office in Munich on 12th November 2008. The EPO Technical Board of Appeal dismissed objections against the patent raised by Institut Pasteur on 12th April 2007. SCS' IRES (Internal Ribosome Entry Site) technology enables researchers to monitor the activity of a gene of interest in living cells or tissues without blocking the normal function of the gene. In particular, IRES is important for evaluating the success of gene deletions (knock-outs) or insertions (knock-ins) in stem cells, which is crucial for the successful creation of transgenic mouse and rat disease models.

Patent licensing after the Quanta decision

Patent owners have turned their attention to the terms and conditions of patent licenses now that the Supreme Court has recently expanded the scope of patent exhaustion through its Quanta Computer v. LG Electronics decision. "Patent exhaustion" is a term of art that generally means a patent owner can profit from the sale of a product covered by the patent only until the first sale of the product.

Microsoft Employee Admits That Patent Disclosure Is A Myth

Defenders of the patent system quite frequently point out that one of the main benefits (some claim the only benefit) of the patent system is "disclosure." That is, because the patent system requires you to disclose your patent, the patent system is quite helpful in spreading ideas. This is a myth that's easily debunked on a few points. First, it only really makes sense to get patent protection if you know the idea will get disclosed or figured out anyway. In those cases, the disclosure via the patent system is meaningless, since the info would have gotten out anyway. Second, these days, thanks to "willful infringement" tripling the damages you pay, many corporations tell employees not to look at relevant patents, as it only opens up more liability.

Stem Cell Sciences Reinforces its International Patent Position in Stem Cell Technologies

Stem Cell Sciences plc (AIM:STEM, ASX:STC) announces that European patent no. 0695361 covering its IRES technology was upheld by the European Patent Office in

VIZIO Comments on Pending Litigation: Certain Patent Claims By Funai Electric Co....

VIZIO Comments on Pending Litigation: Certain Patent Claims By Funai Electric Co. Initially Found to Be Invalid, While the U.S. Patent and Trademark Office Has Initially Found All the Claims to Be Invalid IRVINE, Calif., Nov. 19 /PRNewswire/ -- VIZIO, Inc. announced today that an Administrative Law Judge in the International Trade Commission issued an Initial Determination on Monday, November 17, 2008 with respect to the patent infringement suit it is defending against Funai Electric Co. Funai's complaint had accused multiple HDTV manufacturers including VIZIO of infringing 27 claims in two United States Patents (Nos. 5,329,369 and No. 6,115,074). Of the 27 claims, Funai Electric Co. has, since filing, voluntarily withdrawn 19 of the claims.

Stem Cell Sciences announces validation of European IRES technology patent

UK-based R&D company Stem Cell Sciences has announced that the European patent covering its IRES technology was upheld by the European Patent Office in Munich. The EPO Technical Board of Appeal dismissed objections against the patent raised by Institut Pasteur on April 12, 2007.

Arkados Awarded Patent on Universal Network Adapter Technology

announced today that it has been awarded a United States patent entitled "Integrated Universal Network Adapter." The U.S. Patent & Trademark Office awarded patent 7,440,443 to Arkados on August 2, 2008. The patent describes the concept of making physical network connections transparent to the user, by incorporating MAC/PHY technology that can adapt to different physical media into a single chip. In turn, this chip can be used to create products that can bridge between different physical media connections. The patent also describes a technique to dynamically choose the best medium to use based on data about the medium and the QoS requirements. The patent describes a common Medium Access Controller (MAC) and Physical Layer (PHY) communications interface that has an adapter allowing simultaneous communication over multiple media, such as pow

VIZIO Comments on Pending Litigation: Certain Patent Claims By Funai Electric Co. Initially Found to Be Invalid, While the U.S. Patent and Trademark Office Has Initially Found All the Claims to Be Invalid

VIZIO Comments on Pending Litigation: Certain Patent Claims By Funai Electric Co. Initially Found to Be Invalid, While the U.S. Patent and Trademark Office Has Initially Found All the Claims to Be Invalid

Benitec gets 'Control of Gene Expression' patent in New Zealand

Benitec Limited announced that a key patent 'Control of Gene Expression' part of the Graham patent family of RNA interference (RNAi) patents was granted in New Zealand. The "Control of Gene Expression patent" is a patent in the foundational Graham RNAi patent family and is related to the '099 patent currently under re-examination at the USPTO.

Ameranth Receives Major Patent for Its 'Casino Poker and Dealer Management System'

SAN DIEGO, Oct. 15 /PRNewswire/ -- Ameranth, Inc. announced today that it has received an official patent grant (#7,431,650) from the United States Patent and Trademark Office for a major patent, which will have a term extending to December 2025, on its revolutionary, automated poker and dealer system invention. The patent is the result of work dating from 2001. The award of this key strategic patent confirms Ameranth's leading and pioneering role in automating the modern poker room and clearly establishes Ameranth as a technology leader in virtually all automated aspects of poker rooms as part of Ameranth's overall 21st Century Casino(TM) vision. This new patent, combined with Ameranth's portfolio of wireless/web data synchronization patents (applicable to wireless gaming and many other casino applications) and Ameranth's recent and plan

Search took 2.17 seconds.